Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody.

Marsaud C, Marie I, Koné-Paut I.

J Rheumatol. 2014 Aug;41(8):1721-2. doi: 10.3899/jrheum.131291. No abstract available.

PMID:
25086140
2.

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.

Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN; Canakinumab in CAPS Study Group.

Arthritis Res Ther. 2011;13(6):R202. doi: 10.1186/ar3535. Epub 2011 Dec 9.

3.

Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.

Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weißbarth-Riedel E, Schuetz C, Kallinich T, Krause K, Rietschel C, Horneff G, Benseler SM.

Rheumatology (Oxford). 2016 Apr;55(4):689-96. doi: 10.1093/rheumatology/kev416. Epub 2015 Dec 14.

PMID:
26667214
4.

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.

Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jiménez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ.

Ann Rheum Dis. 2011 Dec;70(12):2095-102. doi: 10.1136/ard.2011.152728. Epub 2011 Aug 21.

PMID:
21859692
5.

Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.

Kanariou M, Tantou S, Varela I, Raptaki M, Petropoulou C, Nikas I, Valari M.

Pediatrics. 2014 Nov;134(5):e1468-73. doi: 10.1542/peds.2013-3185.

6.

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.

Anton J, Calvo I, Fernández-Martin J, Gamir ML, Merino R, Jimenez-Treviño S, Sevilla B, Cabades F, Bou R, Arostegui JI.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S67-71. Epub 2015 Aug 5.

PMID:
26243511
7.

Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.

Church LD, McDermott MF.

Expert Rev Clin Immunol. 2010 Nov;6(6):831-41. doi: 10.1586/eci.10.66.

PMID:
20979548
8.

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S.

Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18. doi: 10.2165/11599820-000000000-00000. Review.

9.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).

Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, Stricker K, Chakraborty A, Tannenbaum S, Wright AM, Rordorf C.

Arthritis Res Ther. 2011 Feb 28;13(1):R34. doi: 10.1186/ar3266.

10.

Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab.

Mueller SM, Itin P, Haeusermann P.

Skinmed. 2013 Mar-Apr;11(2):80-3. No abstract available.

PMID:
23745225
11.

Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.

Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T.

Mod Rheumatol. 2013 May;23(3):425-9. doi: 10.1007/s10165-012-0769-8. Epub 2012 Oct 20. Review.

PMID:
23085882
12.

Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.

Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, Edelsten C, Hawkins PN, Brogan PA.

Rheumatology (Oxford). 2014 Apr;53(4):665-70. doi: 10.1093/rheumatology/ket415. Epub 2013 Dec 17.

PMID:
24352339
13.

[Canakinumab: a promising treatment in rheumatology].

Fabreguet I, So A.

Rev Med Suisse. 2012 Jan 11;8(323):57-60. French.

PMID:
22303742
14.

Corneal response to canakinumab in cryopyrin associated periodic fever syndrome.

Tsatsos M, Hawkin PN, Hossain P.

Br J Ophthalmol. 2013 Aug;97(8):1081-2. doi: 10.1136/bjophthalmol-2013-303429. Epub 2013 Jun 5. No abstract available.

PMID:
23740963
15.

Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.

Savic S, McDermott MF.

Nat Rev Rheumatol. 2009 Oct;5(10):529-30. doi: 10.1038/nrrheum.2009.195. No abstract available.

PMID:
19798026
16.

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, Finetti M, Battagliese A, Martini G, Bibalo C, Martini A, Gattorno M.

Arthritis Res Ther. 2013 Feb 26;15(1):R33. doi: 10.1186/ar4184.

17.

Canakinumab.

Dhimolea E.

MAbs. 2010 Jan-Feb;2(1):3-13. Epub 2010 Jan 15. Review.

18.

Canakinumab: in patients with cryopyrin-associated periodic syndromes.

Curran MP.

BioDrugs. 2012 Feb 1;26(1):53-9. doi: 10.2165/11208450-000000000-00000. Review.

PMID:
22168385
19.

[An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].

Yokota S, Kikuchi M, Nozawa T, Kizawa T, Kanetaka T, Miyamae T, Mori MA, Nishikomori R, Takata H, Heike T, Hara T, Imagawa T.

Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(1):23-9. Review. Japanese.

20.

[Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].

Carné X.

Med Clin (Barc). 2011 Jan;136 Suppl 1:34-7. doi: 10.1016/S0025-7753(11)70007-0. Review. Spanish.

PMID:
21596185

Supplemental Content

Support Center